Furthermore, AZD8055, a dual mTORC1/2 inhibitor, demonstrated significant tumor growth inhibition in high HER-2/neu-expressor endometrial cancers in vitro (English, et al., 2013) as well as in vivo regression in breast, lung, colon, prostate, and uterine xenograft models (Chresta et al., 2010). Here, ERBB2 is linked to neoplasm.